Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with Azacitidine.
Am J Hematol
; 88(9): 780-3, 2013 Sep.
Article
em En
| MEDLINE
| ID: mdl-23757315
ABSTRACT
IPSS-R classifies cytogenetic abnormalities into five prognostic groups for survival. Monosomal karyotype (MK) is not a subgroup of IPSS-R. Additional prognostic information from MK in poor and very poor karyotype has been recently shown. The aim of our study was to determine the prognostic value of IPSS-R and MK for response and survival in AZA-treated high-risk MDS and AML with 20-30% of blasts patients. The study population included 154 patients who were classified according to IPSS-R. IPSS-R was not predictive of response (intermediate, 64%; poor, 44%; very poor, 56%; P = 0.28) or survival (intermediate, 25 months; poor, 12 months; very poor, 11 months; P = 0.14). Twenty-one patients (15%) presented with MK and had a median OS of 9 months. Patients with a very high IPSS-R score without MK had a median OS of 15 months, while patients with a high IPSS-R score without MK had a median OS of 13 months (P = 0.18). We reclassified patients into the following three groups to include MK status very high (MK only; OS median 9 months), high (very high IPSS-R without MK and high IPSS-R without MK; OS median 14 months) and intermediate (OS median 25 months). As in recent publication including MK prognostic, we confirmed that this classification was predictive for survival in AZA treated patients (P = 0.008). IPSS-R failed to discriminate between the prognostic subgroups. Stratification with MK has value in the prognosis of our cohort of AZA-treated patients.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Azacitidina
/
Síndromes Mielodisplásicas
/
Leucemia Mieloide Aguda
/
Cariotipagem
/
Monossomia
/
Antimetabólitos Antineoplásicos
Tipo de estudo:
Prognostic_studies
Limite:
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article